DBV Technologies S.A.

DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Bagneux, France, specializing in immunotherapy treatments for food allergies. The company is known for developing the Viaskin patch, a proprietary transdermal technology designed to administer allergens to intact skin while preventing transfer to the bloodstream. DBV Technologies' primary focus is addressing peanut allergies and cow's milk allergies in pediatric populations, conditions for which limited effective treatment options currently exist. The company's lead candidates include Viaskin Peanut, which aims to help patients tolerate peanut exposure and reduce the risk of severe allergic reactions from accidental exposure, and Viaskin Milk for milk allergy treatment. Viaskin Peanut has received Fast Track designation from the US Food and Drug Administration, reflecting its potential significance in addressing unmet medical needs. Additionally, DBV Technologies developed the E-patch, a standardized diagnostic tool for identifying allergies in children. Founded in 2002, the company operates as a publicly traded biopharmaceutical firm focused on transforming treatment approaches within the immunotherapy field.